Dark Matter Blog

APRIL 4, 2023

The bulk of my nearly three decades of experience up to that point was with drugging protein targets using a variety of modalities, but principally small molecules. It’s all well and good to say, “we should drug RNA,” but which RNA? Prior to 2015, I had a casual relationship, at best, with targeting RNA.

Small Molecule 52

Small Molecule RNA Fragment Screening DNA 52

Drug Target Review

NOVEMBER 1, 2023

Could you provide an overview of your research on target directed cancer drug discovery, particularly your focus on protein lagging interactions. I work in the Centre for Cancer Drug Discovery (CCDD) at The Institute of Cancer Research in London, which is an academic drug discovery centre. 2013) 56, 2059-2073.

Fragment Screening 96

Fragment Screening Biochemical Assays Small Molecule Biophysical Assays 96

Practical Cheminformatics

OCTOBER 8, 2024

While there was a slight chance that my roommates, with no chemistry knowledge, could have accidentally created the structure of a blockbuster drug, it was highly improbable. Examining molecules produced by LLMs gives me a similar impression. It's like someone with no chemistry background is trying to generate a molecule.

Fragment Screening 136

Fragment Screening Packaging Organic Chemistry Small Molecule 136

Sygnature Discovery

JUNE 17, 2024

At Sygnature Discovery, we utilise various biophysical technologies to create assays for diverse targets, integral to every stage of the drug discovery process, from hit identification to candidate selection. Covalent drugs may have advantages over non-covalent molecules, such as greater potency and duration of action.

Small Molecule 52

Small Molecule Fragment Screening DNA Science 52

Sygnature Discovery

JUNE 17, 2024

At Sygnature Discovery, we see biophysics as a core component of drug discovery projects, which can generate data throughout the pipeline. Comprehensive Assay Development for Diverse Applications Our team here at Sygnature Discovery, comprised of expert biophysicists, is highly experienced in a variety of target classes and drug modalities.

Biophysical Assays 52

Biophysical Assays Screening Hits Assay Development Fragment Screening 52

Covalent Modifiers

DECEMBER 3, 2024

Marto SLAS Discovery, 2024 [link] Target-based screening of covalent fragment libraries with mass spectrometry has emerged as a powerful strategy to identify chemical starting points for small molecule inhibitors or find new binding pockets on proteins of interest.

Fragment Screening 59

Fragment Screening Compound Screening Small Molecule Drugs 59